Hu Yu-Long, Ma Qiaoli, Dong Xiaoqiang, Kong Yuanfang, Cai Juntao, Li Jieming, Dong Chunhong
Academy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, China.
Henan Polysaccharide Research Center, Zhengzhou, China.
Front Nutr. 2023 Mar 10;10:1107551. doi: 10.3389/fnut.2023.1107551. eCollection 2023.
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is a leading cause of cirrhosis and hepatocellular carcinoma. Due to its complex pathophysiology, there is currently no approved therapy. Polysaccharide, a kind of natural product, possesses a wide range of pharmacological activities. Numerous preclinical studies have confirmed that polysaccharides could interfere with the occurrence and development of NAFLD at multiple interrelated levels, such as improvement of glucose and lipid metabolism, antioxidation, anti-inflammation, and regulation of gut-liver axis, thus showing great potential as novel anti-NAFLD drugs. In this paper, we reviewed the polysaccharides with anti-NAFLD effect in recent years, and also systematically analyzed their possible pharmacological mechanisms.
非酒精性脂肪性肝病（NAFLD）已成为最常见的慢性肝病，是肝硬化和肝细胞癌的主要病因。由于其复杂的病理生理学，目前尚无获批的治疗方法。多糖作为一种天然产物，具有广泛的药理活性。大量临床前研究证实，多糖可在多个相互关联的水平上干扰NAFLD的发生和发展，如改善糖脂代谢、抗氧化、抗炎以及调节肠-肝轴，因此作为新型抗NAFLD药物具有巨大潜力。本文综述了近年来具有抗NAFLD作用的多糖，并系统分析了其可能的药理机制。
